Holen Sie sich die Stockscreener-App
121.26
2.26%
-2.81
Handel nachbörslich:
121.02
-0.24
-0.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$124.07
Offen:
$124.31
24-Stunden-Volumen:
6.66M
Relative Volume:
0.99
Marktkapitalisierung:
$150.44B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
18.78
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+0.49%
1M Leistung:
+1.24%
6M Leistung:
+11.19%
1J Leistung:
+31.26%
1-Tages-Spanne:
$120.94
$124.57
1-Wochen-Bereich:
$119.33
$124.57
52-Wochen-Spanne:
$90.82
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.26 | 153.93B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,032.97 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
219.57 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.75 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.97 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
143.15 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead stock holds Buy rating at UBS as Yeztugo launch shows promise - Investing.com
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc. - MarketBeat
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes - BioSpace
Gilead Sciences, Inc. (GILD) Stock Analysis: Strong Buy Ratings and 10.84% Potential Upside - DirectorsTalk Interviews
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Manning & Napier Advisors LLC Has $13.65 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD: Morgan Stanley Lowers Price Target for Gilead Sciences | G - GuruFocus
Morgan Stanley Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences stock rating reiterated at Outperform by BMO Capital - Investing.com
Nordea Investment Management AB Has $494.03 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by TD Private Client Wealth LLC - MarketBeat
Liberty One Investment Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Polaris Capital Management LLC Sells 12,500 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead price tries to regain footingForecast today13-01-2026 - Economies.com
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewswire Inc.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Gilead Expects FDA Decision on Anito-Cel in First Quarter of 2026 - Precision Medicine Online
Gilead Sciences: From All-Time Highs To Higher Highs (NASDAQ:GILD) - Seeking Alpha
Gilead’s new HIV prevention shot added to CVS’s drug coverage lists, CEO says - 104.1 WIKY
Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says - Reuters
Sumitomo Mitsui Trust Group Inc. Buys 27,232 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meeder Asset Management Inc. Has $16.76 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Nexus Investment Management ULC Buys 21,220 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Tema Etfs LLC Buys 25,912 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Inside Gilead’s 2030 Strategy to Advance 10 Transformative Therapies - Endpoints News
9,809 Shares in Gilead Sciences, Inc. $GILD Bought by Elite Wealth Management Inc. - MarketBeat
UBS and Citi Go Bullish on Gilead Sciences (GILD) - Insider Monkey
GILD Stock Price, Forecast & Analysis | GILEAD SCIENCES INC (NASDAQ:GILD) - Chartmill
The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration - Yahoo Finance
Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return? - Yahoo Finance
New York State Teachers Retirement System Has $121.45 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Philip James Wealth Mangement LLC Lowers Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead price target raised to $154 from $144 at BofA - Yahoo Finance
Oregon Public Employees Retirement Fund Acquires 34,235 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
HB Wealth Management LLC Buys 13,249 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. (GILD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BofA Securities raises Gilead Sciences stock price target to $154 on HIV franchise strength - Investing.com
Gilead Sciences, Inc. $GILD Position Lessened by Capital Investment Advisors LLC - MarketBeat
Will Gilead Sciences Inc. stock attract ESG investorsJuly 2025 Technicals & Real-Time Buy Signal Notifications - ulpravda.ru
Gilead Names Wettan Executive Vice President - BioXconomy
Gilead (GILD) Recalls Veklury Due to Contaminant Concerns - GuruFocus
What is the fair value of Gilead Sciences Inc. stock now2025 Top Gainers & Risk Controlled Stock Alerts - ulpravda.ru
Gilead presents positive data on liver fibrosis treatments - The Pharma Letter
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
Gilead Sciences posts falling sales and profits, as CEO announces departure - The Pharma Letter
Gilead Sciences, Inc. $GILD Holdings Decreased by Commonwealth Equity Services LLC - MarketBeat
Today's Analyst Action: Citigroup Raises Gilead Sciences (GILD) Price Target | GILD Stock News - GuruFocus
Citigroup Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $140.00 - MarketBeat
UBS Raises Gilead Sciences (GILD) Price Target to $145 and Upgra - GuruFocus
Gilead Sciences (NASDAQ:GILD) Given Buy Rating at UBS Group - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):